Dual FasTCAR T-Cell Therapy Effective Against Multiple Myeloma
GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed…
Somi Igbene, PhD, science writer — 
Articles by Somi Igbene
Telo, Mayo Clinic Working on Tests to ID Patients at Risk of Relapse
Telo Genomics has teamed up with the Mayo Clinic to develop tests to help clinicians identify multiple myeloma (MM) patients at high risk of…
1st CAR T-Cell Therapy in China for Myeloma Now Under Review
The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first chimeric antigen receptor (CAR) T-cell…
1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100
Biohaven Pharmaceuticals has begun enrolling patients in its Phase 1a/1b trial testing the company’s antibody-recruiting molecule (ARM) called BHV-1100. The trial (NCT04634435) seeks…